D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer,Fabrice Barlesi,Daniel Waterkamp,Keunchil Park,Fortunato Ciardiello,Joachim von Pawel,Shirish M. Gadgeel,Toyoaki Hida,Dariusz M. Kowalski,Manuel Cobo Dols,Diego Cortinovis,Joseph W. Leach,Jonathan Polikoff,Carlos H. Barrios,Fairooz F. Kabbinavar,Osvaldo Arén Frontera,Filippo de Marinis,Hande Turna,Jong Seok Lee,Marcus Ballinger,Marcin Kowanetz,Pei He,Daniel S. Chen,Alan Sandler,David R. Gandara +24 more
TL;DR: Overall survival was significantly longer with atezolizumab in the ITT and PD-L1-expression populations, and overall survival improvement was similar in patients with squamous non-squamous lung cancer.
Journal ArticleDOI
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Giorgio V. Scagliotti,Purvish M. Parikh,Joachim von Pawel,Bonne Biesma,Johan Vansteenkiste,Christian Manegold,Piotr Serwatowski,Ulrich Gatzemeier,Raghunadharao Digumarti,Mauro Zukin,Jin S. Lee,Anders Mellemgaard,Keunchil Park,Shehkar Patil,Janusz Rolski,Tuncay Göksel,Filippo de Marinis,Lorinda Simms,Katherine P. Sugarman,David R. Gandara +19 more
TL;DR: This is the first prospective phase III study in NSCLC to show survival differences based on histologic type and cisplatin/pemetrexed provides similar efficacy with better tolerability and more convenient administration than cis platin/gemcitabine.
Journal ArticleDOI
Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Timothy Winton,Robert B. Livingston,David H. Johnson,James R. Rigas,Michael R. Johnston,Charles Butts,Yvon Cormier,Glenwood D. Goss,Richard Inculet,Eric Vallières,Willard A Fry,Drew Bethune,Joseph Ayoub,Keyue Ding,Lesley Seymour,Barbara Graham,Ming-Sound Tsao,David R. Gandara,Kenneth A. Kesler,Todd L. Demmy,Frances A. Shepherd +20 more
TL;DR: Adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs disease-free and overall survival among patients with completely resected early-stage non-small-cell lung cancer.
Journal ArticleDOI
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi,Julien Mazieres,David Planchard,Thomas E. Stinchcombe,Grace K. Dy,Scott J. Antonia,Leora Horn,Hervé Lena,Elisa Minenza,Bertrand Mennecier,Gregory A. Otterson,Luis T. Campos,David R. Gandara,Benjamin Levy,Suresh G. Nair Md,Gérard Zalcman,Jürgen Wolf,Pierre Jean Souquet,Editta Baldini,Federico Cappuzzo,Christos Chouaid,Afshin Dowlati,Rachel E. Sanborn,Ariel Lopez-Chavez,Christian Grohe,Rudolf M. Huber,Christopher T. Harbison,Christine Baudelet,Brian Lestini,Suresh S. Ramalingam +29 more
TL;DR: Nivolumab has clinically meaningful activity and a manageable safety profile in previously treated patients with advanced, refractory, squamous non-small cell lung cancer and these data support the assessment of nivolumsab in randomised, controlled, phase 3 studies of first-line and second-line treatment.
Journal ArticleDOI
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
Kathy S. Albain,R. Suzanne Swann,Valerie W. Rusch,Andrew T. Turrisi,Frances A. Shepherd,Colum Smith,Yuhchyau Chen,Robert B. Livingston,Richard H. Feins,David R. Gandara,Willard A Fry,Gail Darling,David H. Johnson,Mark R. Green,Robert C. Miller,Joanne Ley,Willliam T Sause,James D. Cox +17 more
TL;DR: The primary endpoint was overall survival (OS) and an exploratory analysis, OS was improved for patients who underwent lobectomy, but not pneumonectomy, versus chemotherapy plus radiotherapy, compared with standard concurrent chemotherapy and definitive radiotherapy without resection.